Clinical Trial Detail

NCT ID NCT03233204
Title Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

neuroblastoma

pediatric osteosarcoma

pediatric ependymoma

non-Hodgkin lymphoma

Advanced Solid Tumor

Ewing sarcoma

hepatoblastoma

rhabdomyosarcoma

histiocytosis

childhood medulloblastoma

malignant glioma

Therapies

Olaparib

Age Groups: adult child

Additional content available in CKB BOOST